# Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma

> **NCT05451407** · PHASE1 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** TQB2618 injection
- **DRUG:** Toripalimab injection

## Key facts

- **NCT ID:** NCT05451407
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-09
- **Primary completion:** 2023-10
- **Final completion:** 2023-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05451407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05451407, "Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05451407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*